You are here
Funding
New Funding Opportunities
Notice | Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Collaborative Research Centers (CRCs) (U54 Clinical Trial Optional) |
---|---|
Notice Number | |
Post Date | April 4, 2023 |
Expiration Date | June 16, 2023 |
Notice | Understanding Neurological Effects of COVID-19 and Post-Acute Sequelae of SARS-CoV-2 Infection (R01 Clinical Trial Optional) |
---|---|
Notice Number | |
Post Date | March 29, 2023 |
Expiration Date | February 3, 2024 |
Notice | Understanding Neurological Effects of COVID-19 and Post-Acute Sequelae of SARS-CoV-2 Infection (R21 Clinical Trial Optional) |
---|---|
Notice Number | |
Post Date | March 29, 2023 |
Expiration Date | February 3, 2024 |
Notice | Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (R01 Clinical Trials Not Allowed) |
---|---|
Notice Number | |
Post Date | April 13, 2020 |
Expiration Date | March 6, 2023 |
Notice | Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (R21 Clinical Trial Not Allowed) |
---|---|
Notice Number | |
Post Date | April 13, 2020 |
Expiration Date | May 8, 2023 |
Past Funding Opportunities
Notice | Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Collaborative Research Centers (CRCs) (U54 Basic Experimental Studies Involving Humans Allowed) |
---|---|
Notice Number |
Notice | Data Management and Coordinating Center (DMCC) for the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Collaborative Research Centers (CRC) (U24 Basic Experimental Studies with Humans Required) |
---|---|
Notice Number |
Notice | Clinical Validation of a Candidate Biomarker for Neurological Disease (U01 Clinical Trial Optional) |
---|---|
Notice Number |
Notice | Analytical Validation of a Candidate Biomarker for Neurological Disease (U01 Clinical Trial Optional) |
---|---|
Notice Number |
Notice | Analytical Validation of a Candidate Biomarker for Neurological Disease (U44 Clinical Trial Optional) |
---|---|
Notice Number |
Notice | Clinical Validation of a Candidate Biomarker for Neurological Disease (U44 Clinical Trial Optional) |
---|---|
Notice Number |
This page last reviewed on April 13, 2023